Drug Profile
Anti-CD19 chimeric antigen receptor T cell therapy - The Beijing Pregene Science and Technology Company
Alternative Names: CART-19 cells - Beijing Pregene Science and Technology Company; CD19 specific chimeric antigen receptor T-cells - Beijing Pregene Science and Technology CompanyLatest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Beijing Pregene Science and Technology
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II B-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in B-cell lymphoma(In the elderly, Second-line therapy or greater, In adults) in China (IV)
- 01 Aug 2017 Phase-I/II clinical trials in Acute lymphoblastic leukaemia (In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in China (Parenteral) (NCT03263208)
- 01 May 2017 Phase-I/II clinical trials in B-cell lymphoma (In the elderly, Second-line therapy or greater, In adults, Adjunctive treatment, Refractory metastatic disease) in China (IV) (NCT03146533)